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INTRODUCTION
Currently, topical steroid treatment is considered a basic ther-
apeutic regimen for various inflammatory skin diseases, rang-
ing from acute contact dermatitis to chronic atopic dermatitis. 
However, even with their potent anti-inflammatory activity, a 
number of concerns exist around chronic and uncontrolled use 
of topical steroids due to local and systemic adverse effects.
1 
Concerns are especially high with respect to atopic dermatitis 
(AD) patients due to the chronic nature of the disease and rela-
tively low age of patients. Topical steroids cause diverse local 
and systemic adverse effects, two of which are skin atrophy and 
systemic absorption. These adverse events are considered im-
portant reasons for the widespread steroid-phobia in AD pa-
tients.
2,3 Previous research has also suggested that topical ste-
roids result in a reduction in the synthesis of epidermal lipids, 
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the precursors for the stratum corneum intercellular lipids, lead-
ing to impairment in skin barrier function.
4,5 Disturbed skin 
barrier function is a major pathophysiological factor in AD,
6 and 
further aggravation induced by topical steroids might result in a 
worsening of basal skin conditions.
In addition to the topical steroid, appropriate use of moistur-
izers is considered a baseline therapy for AD, as they can improve 
and reinforce the skin barrier function.
7 Among the diverse com-
ponents comprising the intercellular lipids, ceramide, choles-
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Purpose:  Various therapeutic approaches have been suggested for preventing or reducing the adverse effects of topical glucocorticoids, including 
skin barrier impairment. Previously, we have shown that impairment of skin barrier function by the highest potency topical glucocorticoid, clobetasol 
17-propinate (CP), can be partially prevented by co-application of a physiological lipid mixture containing pseudoceramide, free fatty acids, and cho-
lesterol (multi-lamellar emulsion [MLE]). Skin atrophic effects of CP were also partially reduced by MLE. In this study, the preventive effects of MLE 
on the lowest potency topical glucocorticoid, hydrocortisone (HC), were investigated using animal models.  Methods:  Anti-inflammatory activity of 
topical HC was evaluated using a 12-O-tetradecanoylphobol-13-acetate-induced skin edema model. Topical steroid induced adverse effects were 
evaluated using hairless mouse.  Results:  The results showed that the anti-inflammatory activity was not altered by co-application of either MLE 
or hydrobase. However, co-application of MLE and 1.0% HC showed less impairment in the epidermal permeability barrier function, skin hydration, 
and skin surface pH compared with hydrobase. Stratum corneum integrity, evaluated by measuring trans-epidermal water loss after repeated tape 
stripping, showed less damage with MLE co-application. Long-term application of topical HC induced skin atrophy, measured by a reduction in skin-
fold and epidermal thickness and in the number of epidermal proliferating cell nucleus antigen (PCNA)-positive keratinocytes. Co-application of MLE 
did not affect the skinfold or epidermal thickness, but the number of PCNA-positive keratinocytes was less decreased with MLE use.  Conclu-
sions:  These results suggest that co-application of MLE is effective in reducing the local adverse effects of low-potency topical glucocorticoids and 
supports the therapeutic efficacy of physiological lipid mixtures on skin barrier function.
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terol, and free fatty acids are the main constituents of the lamel-
lar structure of intercellular lipids.
8,9 This structure plays a ma-
jor role in various barrier functions exerted by the skin, and it 
has been reported that a physiological lipid mixture (MLE), con-
taining ceramide, cholesterol, and free fatty acids improves the 
skin barrier function.
10 In addition, research groups, including 
ours, have reported that a pseudoceramide-containing MLE 
can improve skin barrier function.
11-13
Various approaches have been suggested to overcome or min-
imize topical steroid-induced adverse effects including the ap-
plication of physiological lipid mixtures.
5 Topical steroids inter-
fere with the epidermal synthesis of lipid precursors for the stra-
tum corneum, and supplementation with a mixture of physio-
logical lipids can alleviate the steroid-induced skin barrier func-
tion impairment. Previously, we have reported that MLE can 
reduce the adverse effects of the highest potency topical steroid, 
clobetasol 17-propionate (CP).
14 However, relatively low-poten-
cy steroids are usually prescribed and used in AD.
15 In this study, 
we investigated the effects of MLE on hydrocortisone (HC)-in-
duced local adverse effects using animal models. HC (1%) was 
topically applied to normal skin of hairless mice, and either MLE 
or hydrobase was applied simultaneously. Skin barrier func-
tions and skin atrophic effects were measured by non-invasive 
methods and histological observations. Anti-inflammatory ac-
tivity of topical HC was also measured in a 12-O-tetradecanoyl-
phobol-13-acetate-induced skin edema model using the ICR 
mouse.
MATERIALS AND METHODS
Materials
Female hairless mice (hr-/hr-) (6 to 8 weeks old) and ICR 
mice (4 weeks old) (Hanlim Animal Center, Hwasung, Korea) 
were maintained under controlled humidity (50–60% relative 
humidity) and temperature (24°C±1°C) during the experimen-
tal period. The animals were fed a standard diet and tap water 
ad libitum. HC was dissolved in polyethylene glycol (molecular 
weight 400) and ethanol mixture (PEG400: EtOH=70:30) at 1% 
concentration (Chemicals purchased from Sigma-Aldrich Che-
mical, St. Louis, MO, USA). Preparation of pseudoceramide 
containing MLE was performed as previously reported.
11 Stea-
ric acid, cholesterol, and fatty acid triglycerides were obtained 
from Junsei Chemical (Tokyo, Japan). Glycerin monostearate, 
poly oxyethylene (15) glyceryl monostearate were obtained 
from Nihon Emulsion (Tokyo, Japan). Cetanol and squalane 
were purchased from Kao Co. (Tokyo, Japan) and Kishimoto 
(Hyogo, Japan), respectively. Pseudoceramide (myristyl/palmi-
tyl oxostearamide/arachiamide MEA: PC-9S) was acquired from 
NeoPharm Co., Ltd. (Daejeon, Korea). Hydrobase was prepared 
with spermaceti wax, stearyl alcohol, polyethanol glycol (Mw 
4,000), glycerine, cetanol, and sodium lauryl sulphate.
Animal experiments
Animal experiments were performed according to Interna-
tional Guiding Principles for Biomedical Research Involving 
Animals, and protocols were approved by the institutional re-
view board of NeoPharm Co., Ltd. Anti-inflammatory activity of 
steroids was observed by topically applying 1.5 µg of 12-O-tet-
radecanoylphobol-13-acetate (TPA) (Sigma-Aldrich Chemical) 
in 20 µl of acetone (Sigma-Aldrich Chemical) to the right ear of 
the ICR mice. HC solution (30 mg of 1%) was topically applied 
to the same ear after 10 minutes, followed immediately by 30 
mg of either MLE or hydrobase (n=7 for each group). Six hours 
after TPA application, the animals were sacrificed by cervical 
dislocation, and skin from the ear was taken using a 6-mm 
punch. The skin section was weighed, and anti-inflammatory 
activity was calculated as % of weight increase by topical treat-
ment, compared with the control.
Steroid-induced local adverse effects were observed in a fur-
ther experiment spanning a 6-day period of topical HC applica-
tion on hairless mouse skin. Topical HC was applied once a day 
for 6 days, and either MLE or hydrobase was topically applied 
on the same site twice a day, at 10 minutes and 12 hours after 
the HC application. To evaluate the recovery of skin functions, 
the application of MLE or hydrobase was continued for 3 days 
after the completion of the topical steroid treatment. Epidermal 
permeability barrier function, skin hydration, and skin surface 
pH were evaluated by measuring trans-epidermal water loss 
(TEWL), skin surface capacitance, and skin surface pH, respec-
tively. To achieve these measurements, a TEWameter TM300, a 
Corneometer CM 825, and a Skin-pH-Meter PH 905 were used 
(Equipment purchased from Courage & Khaza, Cologne, Ger-
Fig. 1.  Anti-inflammatory activity of topical hydrocortisone (HC) with multi-la-
mellar emulsion (MLE) and hydrobase. Co-application of either MLE or hydro-
base did not inhibit ear weight increase by TPA application, compared with HC 
only treatment. MLE or hydrobase was applied 10 min after TPA application. 
After 6 hr, ear skin was taken with a 6-mm punch, tissue weight was mea-
sured, and inhibitory activity was calculated.
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many). Skin atrophic effects were evaluated by measuring skin-
fold thickness. Three sites were randomly selected from each 
treated area, and skinfold thickness was measured using digital 
calipers (Mitutoyo, Tokyo, Japan).
 To assess skin barrier integrity after steroid application, TEWL 
was measured after repeated tape stripping (10 times) with D-
Squame (CuDerm, Dallas, TX, USA).
Histological assessments
Skin biopsies were taken from the treated site post-HC treat-
ment, fixed with 4% paraformaldehyde solution, and embed-
ded in paraffin. Sections of 5 µm were prepared on probe-on-
plus slides (Fisher Scientific, Pittsburg, PA, USA) and deparaf-
finized. Slides were stained using hematoxylin and eosin stain 
and immunohistochemical stain against proliferating cell nu-
clear antigen (PCNA) and viewed under light microscopy (Olym-
pus BX51, Olympus Co., Tokyo, Japan).
Statistical analysis
Data are expressed as arithmetic mean±standard deviation. 
Analyses were performed using two-tailed Student’s t-test, and 
the results were considered statistically significance at P<0.05.
RESULTS
Anti-inflammatory activity of topical hydrocortisone
To examine whether simultaneous application of pseudocer-
amide containing MLE with topical HC formulation affected 
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Fig. 2.  Change of skin functions during topical steroid treatment. Topical hy-
drocortisone treatment-induced skin barrier impairments, represented by an in-
crease in trans-epidermal water loss (A), reduction of skin hydration (B), and in-
crease in skin surface pH (C). After discontinuation of steroid treatment, resto-
ration of skin hydration and skin surface pH were observed after 3 days. Co-ap-
plication of pseudoceramide-containing multi-lamellar emulsion showed less 
impairment in all the measured parameters compared with hydrobase.Effects of MLE on Steroid Induced Adverse Effects AAIR 
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the anti-inflammatory activity of the steroid, a TPA-induced skin 
edema model was used. Increased ear weight induced by topi-
cal application of TPA was significantly inhibited by topical HC. 
The inhibitory effects were equal for both the hydrobase and 
MLE co-applied sites, compared with HC only (Fig. 1). This re-
sult indicates that simultaneous application of MLE does not 
affect the anti-inflammatory activity of topical steroids.
Skin barrier functions were less impaired with simultaneous 
application of MLE
The local adverse effects of topical glucocorticoids, including 
impairments on skin barrier functions, especially on epidermal 
permeability barrier function, skin hydration, and skin surface 
pH, were measured after simultaneous application with MLE. 
Epidermal permeability barrier function, assessed by measur-
ing TEWL, increased after 6 days of topical HC application. This 
was partially prevented by co-application of MLE. The differ-
ence in TEWL between the two groups was statistically signifi-
cant (P=0.016) (Fig. 2A). Reduction of skin hydration was also 
observed after 2 days of HC application, and the difference be-
tween the two groups was most evident at 3 days, but was not 
statistically significance. Recovery of skin hydration after dis-
continuation of the steroid was observed in both treatment 
groups (Fig. 2B). Skin surface pH gradually increased during 
steroid application, and at 6 days, the difference between the 
two groups was statistically significant (P=0.05). The skin sur-
face pH was rapidly restored by 3 days post-steroid treatment 
(Fig. 2C). Skin barrier integrity was also evaluated by measuring 
TEWL after barrier disruption. Post-steroid application, tape 
stripping was performed on the application site and TEWL was 
measured. After 10 tape strips, the TEWL value was significant-
ly higher in the hydrobase group compared with MLE group, 
suggesting that MLE improved the skin barrier integrity of ste-
roid applied skin (Fig. 3).
MLE alleviated skin atrophy caused by topical hydrocortisone
The effect of topical HC on skin atrophy was investigated by 
measuring skinfold thickness during the application and histo-
logical analysis after steroid treatment. Significant reduction in 
skinfold thickness was observed after 3 days; however, the dif-
ference between the two groups was not significant for the test 
period. Although skin hydration and skin surface pH were re-
stored after completion of the topical steroid treatment, recov-
ery of skinfold thickness was not observed in the same time 
frame (Fig. 4A). Histological observations of the epidermal thick-
ness showed slight but significant differences between the two 
groups (Fig. 4B, C, D). Immunohistochemical staining for PCNA 
confirmed the preventive effects of MLE on the inhibition of 
epidermal proliferation by topical steroids (Fig. 5).
DISCUSSION
We have shown that the co-application of pseudoceramide-
containing physiological lipid mixture (multi-lamellar emul-
sion: MLE) with a low-potency topical corticosteroid reduces 
adverse effects, including impairments in skin barrier functions. 
Adverse events of topical steroids are usually local due to the 
low penetration of steroids through the skin.
1 The local adverse 
effects include atrophic changes, increased infections, and mis-
cellaneous effects such as acne, rosacea, hyper- or hypo-pig-
mentation, and rebound flares.
1 To prevent or reduce these ad-
verse effects, several approaches have been reported to be ef-
fective including the use of lower potency steroids or equipo-
tent steroids with different potency of skin atrophy,
16 alteration 
of application scheme, such as alternate-day therapy,
17 or co-
application with topical tretinoin.
18 Impairment of skin barrier 
functions by topical steroids, expressed as increased TEWL, de-
creased skin hydration, and structural disorganization of the 
stratum corneum intercellular lipids have been reported in vivo 
and through clinical studies.
4,5 Several reports have suggested 
that skin barrier impairment by topical steroids is due to struc-
tural disorganization of the stratum corneum intercellular lipid 
lamellar structure.
19 In addition, the increase in skin surface pH 
observed after topical steroid treatment is due to the decreased 
synthesis of free fatty acid precursors in viable epidermis.
14
The stratum corneum, the outermost layer of the skin, plays 
the most important role in barrier functions, including epider-
mal permeability, hydration, and anti-microbial functions.
9 The 
most widely used structural model for the stratum corneum is 
the ‘brick and mortar’ model, describing the corneocytes as 
‘bricks’ and intercellular lipids as ‘mortar.’
8 Previous studies 
have suggested that the structural arrangement of intercellular 
lipids into the distinctive lamellar structure is the most impor-
tant factor for those barrier functions, and defects or disorgani-
Fig. 3.  Skin barrier integrity assessed by change of trans-epidermal water loss 
(TEWL) after tape stripping. After 10 strips, TEWL was significantly higher in 
the hydrobase co-applied site compared with the multi-lamellar emulsion (MLE) 
co-applied site.
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zation of the lamellar structure results in impaired skin barrier 
functions.
20 Several precursor molecules comprising the inter-
cellular lipids are synthesized in the keratinocytes in viable epi-
dermis and transported into the stratum corneum layer through 
the lamellar bodies. Extracellular processing of the precursor 
molecules in the stratum corneum produces the lipid compo-
nents for the lamellar structure. Due to the inhibitory effects of 
topical steroids on the lipid precursor synthesis in keratinocytes, 
impairments of the lamellar structure in the stratum corneum 
are induced, resulting in a disturbance of skin barrier function. 
In previous reports, an equimolar mixture of the major constit-
uents of human stratum corneum intercellular lipids, i.e., free 
fatty acid, cholesterol, and ceramide, showed beneficial effects 
in restoring the permeability barrier functions and stratum cor-
neum integrity.
5 Although the highest potency topical steroid, 
CP was used in previous studies and the lowest potency topical 
steroid, HC, was used in this study, similar results were observed 
for skin barrier functions. Increase of TEWL, decrease of skin 
hydration, increase of skin surface pH, and disturbed stratum 
corneum integrity were observed after 6 days of topical HC ap-
plication. Consistent with previous studies, co-application of 
pseudoceramide containing MLE resulted in nearly identical 
lamellar structure in the naive human stratum corneum, pre-
venting topical steroid-induced adverse effects.
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AD, characterized by impaired skin barrier function and im-
munologic disturbance, is a chronic inflammatory skin disease 
and usually requires a long treatment duration.
21 Diverse thera-
peutic regimens have been used for the treatment of AD, but 
the cornerstone therapy is moisturizers and topical steroids. 
Physiological lipid mixtures, due to their efficacy of improving 
skin barrier function, have been suggested to have beneficial 
effects on the management of AD.
22 Because the skin barrier 
function of AD patients is already compromised, topical steroid 
treatment can interfere or cause the deterioration of the skin 
barrier function, which necessitates the use of skin barrier-en-
hancing moisturizers. Along with improvements in the skin 
barrier function, these results confirm the beneficial effects of 
physiological lipid mixtures in reducing topical steroid-induced 
adverse effects.
Consistent with a previous study, as well as skin barrier func-
tion improvement, skin atrophy was slightly prevented by MLE. 
Demerjian et al.
23 reported that the activator of peroxisome pro-
liferator-activated receptor (PPAR)-α, PPARβ/δ and liver X re-
ceptor (LXR) can partially prevent the decrease in keratinocyte 
proliferation in topical steroid treated murine skin. PPARα, β/ δ, 
and LXR activators are known to exert diverse effects on epider-
mal structure and functions, including anti-inflammatory ef-
fects. Moreover, the activators also improve the epidermal per-
meability barrier function, mainly due to the stimulating activi-
ty on the epidermal lipid synthesis, which is required for stra-
tum corneum intercellular lipid formation. In addition, PPAR 
and LXR activators also regulate keratinocyte proliferation.
24 In 
this study, myristyl/palmitoyl oxostearamide/arachinamide 
MEA (PC-9S) was used as a pseudoceramide for physiological 
lipid preparation. The chemical structure of PC-9S is similar to 
that of palmitoylethanolamine, which was previously reported 
as having PPAR activating effects,
25 and according to our pre-
liminary studies, PC-9S showed significant PPAR activating ef-
fect in cultured human keratinocytes. Although further investi-
gation is required, the PPAR-activating effects of PC-9S might 
be a possible explanation for the beneficial effects of MLE.
In conclusion, our study showed that the co-application of 
MLE prevents topical steroid-induced adverse effects. Skin bar-
rier function impairments and inhibition of keratinocyte prolif-
Fig. 5.  Reduction of epidermal proliferation by topical hydrocortisone (HC) 
treatment. proliferating cell nucleus antigen (PCNA) staining on skin biopsy 
samples showed a decrease in the number of PCNA-positive keratinocytes in 
the basal layer after 6 days of HC treatment compared with that in normal skin 
(represented by dotted line) (A). Multi-lamellar emulsion (MLE) co-application 
partially prevented the reduction of PCNA-positive keratinocytes (B) compared 
with hydrobase (C).
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eration were partially reduced by MLE. These results suggest 
that the use of physiological lipid mixtures with topical steroids 
can be a beneficial therapeutic option, especially for AD pa-
tients.
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